



Zedira communication

CHDI Foundation names Zedira as supplier for R&D products



CHDI Foundation, Inc. names Zedira as supplier for transglutaminase biochemicals. Douglas Macdonald, Director, Drug Discovery points out: "Zedira provides unique specialty reagents for research and development in the area of human transglutaminases. We are very satisfied with the quality of the products and with the reliable delivery of the reagents combined with an excellent scientific support".

The results of CHDI compound screening performed in cooperation with Evotec AG were recently published (Schaertl et al., J Biomol Screen. 2010 Jun;15(5):478-87. Epub 2010 Apr 15).

About CHDI

CHDI Foundation, Inc. is a privately-funded, not-for-profit, virtual biotech company that works with an international network of scientists to rapidly discover and develop therapies that slow the progression of Huntington's disease (HD). One of the targets under evaluation is tissue transglutaminase (TG2).

This communication is published by:

Zedira GmbH

Roesslerstr. 83

64293 Darmstadt, Germany

Phone: +49 6151 3251-00

Fax: +49 6151 3251-19

Web: www.zedira.com

E-mail: contact@zedira.com

© 2010, Zedira GmbH